This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts
by Kinjel Shah
J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines
Optimism Back in Wall Street? ETFs Areas to Win the Most
by Sanghamitra Saha
Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.
Pfizer (PFE) Stock Moves -1.26%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $35.98, marking a -1.26% move from the previous day.
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up
by Ritujay Ghosh
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
by Ekta Bagri
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
Pfizer (PFE) Progressing Well With its Coronavirus Program
by Zacks Equity Research
Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.
Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak
by Zacks Equity Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
Top Analyst Reports for Alibaba, Pfizer & S&P Global
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Pfizer (PFE) and S&P Global (SPGI).
Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer
by Zacks Equity Research
Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.
J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports first-quarter results.
Merck's Keytruda Gets FDA's Priority Review for Solid Tumors
by Zacks Equity Research
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.
Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
by Sweta Jaiswal, FRM
The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
These Medical ETFs & Stocks Deserve a Salute on Health Day
by Sanghamitra Saha
The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.
3 Stocks Immune to the Coronavirus Downturn to Buy Right Now
by Benjamin Rains
Today's episode of Full Court Finance here at Zacks quickly dives into why Wall Street seems optimistic on Monday. Despite the positivity, investors should still be on the hunt for stocks that appear immune to the broader coronavirus fallout...
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates
by Kinjel Shah
J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis
by Zacks Equity Research
Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.
Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy
by Benjamin Rains
Eli Lilly (LLY) stock closed the first quarter above where it started, which was no easy task. So let's dive into why investors might want to buy LLY stock right now...
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
by Indrajit Bandyopadhyay
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
Pfizer (PFE) Stock Moves -0.03%: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $32.66 in the latest trading session, marking a -0.03% move from the prior day.
Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus
by Benjamin Rains
AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty...
Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View
by Zacks Equity Research
Vertex (VRTX) announces plan to halt enrollment and delay study initiation amid coronavirus pandemic. However, it does not expect any supply chain disruption and maintains its business outlook for 2020.